Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis,...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2020-12-01
|
Series: | Chronic Diseases and Translational Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095882X20300645 |
id |
doaj-7cdbba4d6c314a6a9f286fa7af3beceb |
---|---|
record_format |
Article |
spelling |
doaj-7cdbba4d6c314a6a9f286fa7af3beceb2021-04-02T18:53:35ZengKeAi Communications Co., Ltd.Chronic Diseases and Translational Medicine2095-882X2020-12-0164239245Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitorsFan Yang0Ran Meng1Da-Long Zhu2Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, Jiangsu 210008, ChinaDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, Jiangsu 210008, ChinaCorresponding author. Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, Jiangsu 210008, China.; Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, Jiangsu 210008, ChinaSodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety.http://www.sciencedirect.com/science/article/pii/S2095882X20300645Sodium-glucose cotransporter-2 inhibitorsType 2 diabetesCardiovascular outcomesMechanisms of cardiovascular benefits |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fan Yang Ran Meng Da-Long Zhu |
spellingShingle |
Fan Yang Ran Meng Da-Long Zhu Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors Chronic Diseases and Translational Medicine Sodium-glucose cotransporter-2 inhibitors Type 2 diabetes Cardiovascular outcomes Mechanisms of cardiovascular benefits |
author_facet |
Fan Yang Ran Meng Da-Long Zhu |
author_sort |
Fan Yang |
title |
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors |
title_short |
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors |
title_full |
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors |
title_fullStr |
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors |
title_full_unstemmed |
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors |
title_sort |
cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors |
publisher |
KeAi Communications Co., Ltd. |
series |
Chronic Diseases and Translational Medicine |
issn |
2095-882X |
publishDate |
2020-12-01 |
description |
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety. |
topic |
Sodium-glucose cotransporter-2 inhibitors Type 2 diabetes Cardiovascular outcomes Mechanisms of cardiovascular benefits |
url |
http://www.sciencedirect.com/science/article/pii/S2095882X20300645 |
work_keys_str_mv |
AT fanyang cardiovasculareffectsandmechanismsofsodiumglucosecotransporter2inhibitors AT ranmeng cardiovasculareffectsandmechanismsofsodiumglucosecotransporter2inhibitors AT dalongzhu cardiovasculareffectsandmechanismsofsodiumglucosecotransporter2inhibitors |
_version_ |
1721550685394173952 |